- Home
- DXR vs GBIO Comparison
DXR vs GBIO Comparison
Compare DXR & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- GBIO
- Stock Information
- Founded
- DXR 1970
- GBIO 2016
- Country
- DXR United States
- GBIO United States
- Employees
- DXR N/A
- GBIO N/A
- Industry
- DXR Medical/Dental Instruments
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- GBIO Health Care
- Exchange
- DXR Nasdaq
- GBIO Nasdaq
- Market Cap
- DXR 40.3M
- GBIO 35.2M
- IPO Year
- DXR N/A
- GBIO 2020
- Fundamental
- Price
- DXR $8.08
- GBIO $0.37
- Analyst Decision
- DXR Strong Buy
- GBIO Strong Buy
- Analyst Count
- DXR 1
- GBIO 4
- Target Price
- DXR $25.00
- GBIO $7.33
- AVG Volume (30 Days)
- DXR 8.9K
- GBIO 447.7K
- Earning Date
- DXR 01-01-0001
- GBIO 03-13-2025
- Dividend Yield
- DXR N/A
- GBIO N/A
- EPS Growth
- DXR 86.16
- GBIO N/A
- EPS
- DXR 0.11
- GBIO N/A
- Revenue
- DXR $119,714.00
- GBIO $19,892,000.00
- Revenue This Year
- DXR N/A
- GBIO N/A
- Revenue Next Year
- DXR N/A
- GBIO $10.90
- P/E Ratio
- DXR $73.78
- GBIO N/A
- Revenue Growth
- DXR N/A
- GBIO 236.92
- 52 Week Low
- DXR $6.55
- GBIO $0.37
- 52 Week High
- DXR $10.00
- GBIO $4.52
- Technical
- Relative Strength Index (RSI)
- DXR 55.84
- GBIO 27.19
- Support Level
- DXR $8.02
- GBIO $0.48
- Resistance Level
- DXR $8.50
- GBIO $0.50
- Average True Range (ATR)
- DXR 0.42
- GBIO 0.05
- MACD
- DXR -0.01
- GBIO 0.00
- Stochastic Oscillator
- DXR 35.56
- GBIO 3.11
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.